GYBYS(600332)2025-04-29 09:40Financial Performance - The company's operating revenue for Q1 2025 was CNY 22,473,408,393, a decrease of 2.06% compared to CNY 22,946,211,892 in the same period last year[4]. - Net profit attributable to shareholders was CNY 1,821,313,254, down 6.99% from CNY 1,958,118,124 year-on-year[4]. - Basic and diluted earnings per share were both CNY 1.120, a decrease of 6.99% from CNY 1.204 in the same period last year[4]. - Total operating revenue for Q1 2025 was CNY 22,473,408,392.77, a decrease of 2.06% from CNY 22,946,211,891.84 in Q1 2024[20]. - Net profit for Q1 2025 was CNY 1,857,449,310.65, a decrease of 8.54% compared to CNY 2,031,724,927.91 in Q1 2024[21]. - The company’s total comprehensive income for Q1 2025 was CNY 1,850,877,925.86, down from CNY 2,033,231,749.61 in Q1 2024[22]. Cash Flow - The net cash flow from operating activities was negative CNY 3,897,258,025, representing a decline of 24.19% compared to the previous year[4]. - Cash inflow from operating activities in Q1 2025 was CNY 15,913,593,244.88, compared to CNY 16,789,987,378.48 in Q1 2024[23]. - The net cash flow from operating activities was negative at (3,897,258,025.12), compared to (3,138,186,616.77) in the previous period, indicating a decline in operational cash generation[24]. - The total cash and cash equivalents at the end of the period decreased to 12,699,134,891.11 from 18,344,448,005.36, reflecting a significant reduction in liquidity[25]. - The company reported a total cash outflow from operating activities of 19,810,851,270.00, slightly down from 19,928,173,995.25, suggesting stable operational expenses[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 80,047,799,450, a decrease of 2.00% from CNY 81,683,611,521 at the end of the previous year[6]. - The company's current assets totaled ¥55,673,034,339.05, down from ¥57,762,228,309.37, indicating a decrease of about 3.63%[16]. - Total liabilities decreased to ¥40,408,879,746.27 from ¥43,913,975,774.25, a decline of about 8.5%[17]. - The non-current liabilities decreased to ¥4,299,969,166.95 from ¥4,998,286,418.68, indicating a reduction of about 14.0%[17]. Shareholder Information - The equity attributable to shareholders increased by 5.05% to CNY 37,719,037,765 from CNY 35,904,527,869 at the end of the previous year[6]. - The total number of ordinary shareholders at the end of the reporting period was 93,536[12]. - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., held 45.04% of the shares, totaling 732,305,103 shares[12]. Operational Efficiency - The weighted average return on net assets was 4.95%, down 0.5 percentage points from 5.45% at the end of the previous year[6]. - Research and development expenses for Q1 2025 were CNY 143,713,072.16, a decrease of 22.73% from CNY 186,139,000.55 in Q1 2024[20]. - The company paid 1,669,345,024.24 in cash to employees, a decrease from 1,744,322,516.63, indicating cost management efforts[24]. Investment Performance - The company reported an investment income of CNY 131,136,370.42, up from CNY 102,119,649.77 in Q1 2024[20]. - Cash inflow from investment income was 63,221,276.30, up from 32,695,487.98, reflecting improved investment performance[24]. Other Information - The company has not reported any new strategies or product developments during this period[14]. - The impact of exchange rate changes on cash and cash equivalents was positive at 6,328,259.74, compared to 2,432,159.43 previously, indicating some currency gains[24].